Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results
Press ReleaseNicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue 1 €3.9 million) for first quarter 2024Nicox Group cash of €9.1 million on March 31, 2024 which finances the Company until at least November 2024 April 22, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided the...
Nasdaq GlobeNewswire
22/04/2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in…
"Ipsen is an extraordinary company with a deep passion for serving patients, and we are excited to partner with them to expand their pipeline of innovative therapies," said Sergey Paushkin, Chief Scientific Officer at Skyhawk. "Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics." "Ipsen is an extraordinary company with a deep passion for…
PR Newswire
22/04/2024
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further…
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva ®approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and qualitySandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolioBasel, April 22, 2024– Sandoz, the global leader in generic and biosimilar...
Nasdaq GlobeNewswire
22/04/2024
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in…
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape...
Nasdaq GlobeNewswire
22/04/2024
Juniper Biologics Named "Pharmaceutical Company of the Year" at Corporate…
Founded in 2020, Juniper specialises in the development and commercialization of novel therapies in areas with significant unmet needs: Oncology and Oncology Supportive Care, Gene Therapy, and Rare and Orphan Diseases. By focusing on these specialised therapy areas, Juniper strives to provide the next generation of life-changing medicines that can have profound impacts on the lives of patients across the world. Founded in 2020, Juniper specialises in the development and commercialization of...
PR Newswire
22/04/2024
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
"I am very happy that our Brain Transporter technology has continued to progress so well and that we have now entered into this first agreement utilizing this platform. I believe that this technology has huge potential to improve many different projects, and support companies in their pursuit of helping people with brain disorders," said Gunilla Osswald, CEO at BioArctic. "Eisai has been a valuable partner to BioArctic during the past two decades, and we are very pleased to extend…
PR Newswire
20/04/2024
Correction to Company announcement – No. 23 / 2024
Correction to Company announcement – No. 23 / 2024Copenhagen, Denmark, April 19, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has a correction to company announcement No. 23 /2024, April 19, 2024 - regarding transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their...
Nasdaq GlobeNewswire
19/04/2024
CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY…
MagicTouch represents a revolutionary advancement in coronary intervention, offering a controlled and sustained release of Sirolimus, akin to a drug-eluting stent but without the necessity of implanting permanent scaffold. MagicTouch represents a revolutionary advancement in coronary intervention, offering a controlled and sustained release of Sirolimus, akin to a drug-eluting stent but without the necessity of implanting permanent scaffold. "We are thrilled to announce the first…
PR Newswire
19/04/2024
Pharming Group announces the repurchase of outstanding €125 million convertible…
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.Leiden, the Netherlands, 19th April, 2024:Pharming Group N.V. (" Pharming " or the " Company ") (Euronext Amsterdam: PHARM) announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds…
Nasdaq GlobeNewswire
19/04/2024
Carbios files its 2023 Universal Registration Document
Clermont-Ferrand, France, 19 April 2024 (18.30 CEST). Carbios(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, announces to its shareholders and the financial community that its 2023 Universal Registration Document including the annual report, the management report and the report on corporate governance was filed with the French Financial Market Authority (Autorité des...
Nasdaq GlobeNewswire
19/04/2024
FRH requests 60-day extension of Article 5:72(1) of Dutch Financial Supervision…
FRH requests 60-day extension of Article 5:72(1) of Dutch Financial Supervision Act Paris, 19 April 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR0000125585) hereby informs as follows: On behalf of France Retail Holdings S.à.r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH has today submitted a petition to the Enterprise Chamber of the Court of Appeal in Amsterdam, the Netherlands, pursuant to Article 5:72(2) of...
Nasdaq GlobeNewswire
19/04/2024
Transactions in Zealand Pharma shares and/or related securities by persons…
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
19/04/2024
Dr. Sam Barrell CBE appointed as CEO of LifeArc
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive international recruitment process.Sam will join LifeArc from the Francis Crick Institute where she is currently Deputy CEO with responsibility for strategic management and operational leadership, as well as deputising for the Director, Sir Paul...
Nasdaq GlobeNewswire
19/04/2024
Zealand Pharma launches long-term incentive programs for Zealand's Board of…
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024–Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs (the “LTIP”) for Zealand's...
Nasdaq GlobeNewswire
19/04/2024
Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 -…
Peptide therapeutics are emerging as a powerful approach to combat various diseases, owing to their ability to utilize short chains of amino acids to effectively target and treat health conditions. With the prevalence of chronic diseases such as cancer and diabetes, the need for innovative treatments is more significant than ever, highlighting the importance of exploring protein interactions for targeted therapeutic strategies. Challenges include the instability of peptides and the hefty cost of…
PR Newswire
19/04/2024
Sterilization Equipment Market Worth $24.7 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=642 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=642 Browse in-depth TOC on "Sterilization Equipment Market" 281 - Tables 51 - Figures 313 - Pages Sterilization Equipment Market Scope: The sterilization instruments accounted for the largest share of the sterilization equipment market, by product & service segment, in 2023 ...
PR Newswire
19/04/2024
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab…
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platform session at the Annual Meeting of the American Academy of Neurology in Denver, Colorado - NEW YORK, April19, 2024(GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Nasdaq GlobeNewswire
19/04/2024
Alvotech signs U.S. agreement to expand access for newly approved…
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today...
Nasdaq GlobeNewswire
19/04/2024
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin's Prestigious Gold…
Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa's University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now...
Nasdaq GlobeNewswire
19/04/2024
SmartCella strengthens team with Dr Ricardo Baptista as CTO
Niklas Prager, CEO of SmartCella, says: "The appointment of Ricardo as CTO and Head of Procella is yet another important milestone for us as a group, and I am thrilled to continue to strengthen the team with talent of Ricardo's caliber. His extensive experience in the cell and gene therapy field will be instrumental to our strategic framework to advance our targeted cell-based therapies into the clinic. His entrepreneurial mindset will ensure our path to commercialization and will add true…
PR Newswire
19/04/2024
For my beloved family, I leave you my.....fridge freezer! New research from Beko…
77% of UK consumers have inherited at least one common physical household object* whilst jewellery and watches top the list (52%) followed by furniture (31%), clothing (27%) and artwork or decorations (21%). With 17% of those who were surveyed saying they have inherited white goods, such as a washing machine or fridge**, 18% said white goods were an object they were most likely to pass on. The generation most likely to want to inherit white goods were millennials. 77% of UK consumers have...
PR Newswire
19/04/2024
Milk Bottle Market to Reach $5,718.7 Million Globally by 2032 at 5.1% CAGR…
Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A295923 Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A295923 Prime Determinants of Growth The growing population across the globe coupled with the growing demand for dairy and the rapid expansion of e-commerce & online grocery shopping due to on-the-go lifestyle are the factors expected to drive the growth of the global milk bottle...
PR Newswire
19/04/2024
IDTechEx Examines the Opportunities for Wearables in Digital Health
Consumer devices battle for medical applications Consumer devices battle for medical applications A direction of travel that has been evident in thewearables industryis the increase in health metrics monitored by smartwatches. A key development inFebruary 2024was the clearance by the US regulatory body, the Food and Drug Administration (FDA), of the Samsung Galaxy Watch app for the assessment of sleep apnea risk. Sleep apnea is a serious sleep disorder that has significant health...
PR Newswire
19/04/2024
FDA approves Roche's Alecensa as the first adjuvant treatment for people with…
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC) 1 This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy 2 The National Comprehensive Cancer Network® (NCCN®) Guidelines...
Nasdaq GlobeNewswire
19/04/2024
Altri Comunicati
